ArticleCureus2024
CT-Guided Online Adaptive Stereotactic Body Radiotherapy (SBRT) for Retroperitoneal Sarcoma After Previous Radiotherapy: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CT-guided online adaptive radiotherapy (OART) is a novel and robust treatment technique in radiotherapy. Thanks to its excellent accommodation of inter-fraction variations, OART is characterized by superior accuracy compared to other contemporary treatment techniques in radiotherapy such as image-guided radiotherapy (IGRT). Planning target volume (PTV), which takes into account interfraction movements, could therefore be reduced while utilizing OART with a consequent dose reduction for adjacent healthy tissue. Herein we report our successful experience in treating a patient with retroperitoneal sarcoma after previous radiotherapy and surgery. The tumor was in close proximity to the spinal canal and abutted a large bowel segment and the last portions of the duodenum. Radiotherapy regimen consisted of 30 Gy in five fractions. Treatment implementation and delivery were feasible and the treatment was given without any interruptions. After a follow-up period of nine months so far, the patient reported no radiation-related adverse effects. Furthermore, her post-treatment magnetic resonance imaging (MRI) scans demonstrate good radiographic response. Our case highlights the use of OART to treat a challenging case in radiotherapy as it was given in the setting of re-irradiation to a mesenchymal tumor, which is considered exquisitely radio-resistant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.